tetano
Editor, Senior Moderator
NEJM Evid
. 2023 Feb;2(2):EVIDoa2200206.
doi: 10.1056/EVIDoa2200206. Epub 2023 Jan 23. A Pragmatic Randomized Feasibility Trial of Influenza Vaccines
Niklas Dyrby Johansen[SUP] 1 2 [/SUP], Daniel Modin[SUP] 1 2 [/SUP], Joshua Nealon[SUP] 3 [/SUP], Sandrine Samson[SUP] 4 [/SUP], Camille Salamand[SUP] 4 [/SUP], Matthew M Loiacono[SUP] 5 [/SUP], Carsten Schade Larsen[SUP] 6 [/SUP], Anne Marie Reimer Jensen[SUP] 1 2 [/SUP], Nino Emanuel Landler[SUP] 1 2 [/SUP], Brian L Claggett[SUP] 7 [/SUP], Scott D Solomon[SUP] 7 [/SUP], Martin J Landray[SUP] 8 9 [/SUP], Gunnar H Gislason[SUP] 1 10 11 12 [/SUP], Lars Køber[SUP] 10 13 [/SUP], Jens Ulrik Stæhr Jensen[SUP] 14 [/SUP], Pradeesh Sivapalan[SUP] 14 [/SUP], Lasse Skafte Vestergaard[SUP] 15 [/SUP], Palle Valentiner-Branth[SUP] 15 [/SUP], Tyra Grove Krause[SUP] 15 [/SUP], Tor Biering-Sørensen[SUP] 1 2 [/SUP]
Affiliations
Randomized Feasibility Trial of Influenza VaccinesThis pragmatic, open-label, active-controlled, randomized feasibility trial of QIV-HD versus QIV-SD was conducted in Danish citizens aged 65 to 79 years during the 2021-2022 influenza season. Randomization was integrated into routine vaccination practice. Only nationwide administrative health registries were used for data collection.
. 2023 Feb;2(2):EVIDoa2200206.
doi: 10.1056/EVIDoa2200206. Epub 2023 Jan 23. A Pragmatic Randomized Feasibility Trial of Influenza Vaccines
Niklas Dyrby Johansen[SUP] 1 2 [/SUP], Daniel Modin[SUP] 1 2 [/SUP], Joshua Nealon[SUP] 3 [/SUP], Sandrine Samson[SUP] 4 [/SUP], Camille Salamand[SUP] 4 [/SUP], Matthew M Loiacono[SUP] 5 [/SUP], Carsten Schade Larsen[SUP] 6 [/SUP], Anne Marie Reimer Jensen[SUP] 1 2 [/SUP], Nino Emanuel Landler[SUP] 1 2 [/SUP], Brian L Claggett[SUP] 7 [/SUP], Scott D Solomon[SUP] 7 [/SUP], Martin J Landray[SUP] 8 9 [/SUP], Gunnar H Gislason[SUP] 1 10 11 12 [/SUP], Lars Køber[SUP] 10 13 [/SUP], Jens Ulrik Stæhr Jensen[SUP] 14 [/SUP], Pradeesh Sivapalan[SUP] 14 [/SUP], Lasse Skafte Vestergaard[SUP] 15 [/SUP], Palle Valentiner-Branth[SUP] 15 [/SUP], Tyra Grove Krause[SUP] 15 [/SUP], Tor Biering-Sørensen[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38320035
- DOI: 10.1056/EVIDoa2200206
Randomized Feasibility Trial of Influenza VaccinesThis pragmatic, open-label, active-controlled, randomized feasibility trial of QIV-HD versus QIV-SD was conducted in Danish citizens aged 65 to 79 years during the 2021-2022 influenza season. Randomization was integrated into routine vaccination practice. Only nationwide administrative health registries were used for data collection.